It was the first in a series of drugs that are, for the first time, effective against obesity and can help lessen the moral ...

Biocon said that its wholly owned subsidiary, Biocon Biologics announced strategic collaboration agreement with Civica, Inc. to expand access, affordability of Insulin Aspart in the United States.

The global antidiabetics market is on a strong growth trajectory, with sales projected to soar from USD 106.3 billion in 2024 to USD 298.2 billion by 2034. This substantial increase reflects a robust ...

Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...

Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will ...

Civica will start selling the medicine for patients in the United States after completing development work and clinical trials.

Biocon Biologics Ltd and Civica, Inc. today announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States.

People on Ozempic and other GLP-1 agonist drugs commonly report they no longer have constant, incessant thoughts about food.

Biocon Biologics unit and USA-based Civica Rx, a not-for-profit generic drug and pharmaceutical company, have announced a ...

This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the US, which is currently under ...

Biocon Biologics' own Insulin Aspart drug product for the US is currently under review by the US Food and Drug Administration ...